...
首页> 外文期刊>Circulation. Arrhythmia and electrophysiology >Use of an implantable monitor to detect arrhythmia recurrences and select patients for early repeat catheter ablation for atrial fibrillation: a pilot study.
【24h】

Use of an implantable monitor to detect arrhythmia recurrences and select patients for early repeat catheter ablation for atrial fibrillation: a pilot study.

机译:使用植入式监护仪检测心律失常的复发并选择患者进行早期重复导管消融以进行房颤:一项先导研究。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Catheter ablation of atrial fibrillation (AF) has proved effective in curing highly symptomatic patients with paroxysmal AF. The aim of this prospective, randomized study was to identify the optimal treatment of patients with AF recurrences after the first ablation. METHODS AND RESULTS: Two hundred eighty-six patients with paroxysmal AF underwent ablation (circumferential pulmonary vein isolation with linear lesions) and were monitored with an implantable cardiac monitor (Reveal XT, Medtronic). Patients without AF recurrences during the 3-month postablation period were assigned to group 1; those with AF recurrences to group 2. Patients in group 2 were randomly assigned to group 3 or group 4. Group 3 patients were treated only with antiarrhythmic drugs for 6 weeks, with no early reablation during the 3-month postablation period. In the case of AF recurrence after the 3-month postablation period, patients underwent reablation. Group 4 patients were treated according to the onset mechanism of AF recurrences, as detected and stored by the implantable cardiac monitor: antiarrhythmic drug therapy, but no reablation if AF was not preceded by triggers; early reablation if premature atrial beats or atrial tachycardias or flutter triggered AF. All patients were followed up for 1 year to assess maintenance of sinus rhythm in each group. On 12-month follow-up examination, of the 119 (42%) patients in group 1, 112 (94%) had no AF recurrences. Among the 83 patients in group 3, only 27 (33%) had no recurrences. Of the 84 group 4 patients, 67 (80%) had no AF recurrences (P<0.0001 versus group 3). CONCLUSIONS: Patients with recurrences after the first AF ablation are likely to respond to a second early ablation when AF is triggered by supraventricular arrhythmias or premature contractions. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01164319.
机译:背景:经导管消融房颤(AF)已被证明可有效治愈症状强烈的阵发性AF患者。这项前瞻性随机研究的目的是确定首次消融后AF复发患者的最佳治疗方法。方法和结果:286例阵发性房颤患者进行了消融术(行肺静脉隔离并伴有线性病变),并通过植入式心脏监护仪(Reveal XT,Medtronic)进行了监测。消融后3个月内无房颤复发的患者被分配为第1组;房颤复发至第2组的患者。第2组的患者被随机分配到第3组或第4组。第3组的患者仅接受抗心律失常药物治疗6周,在消融后的3个月内没有早期消融。在消融后3个月后出现AF复发的情况下,患者应进行消融。第4组患者根据房颤复发的发病机制进行了治疗,该机制由植入式心脏监护仪检测和存储:抗心律失常药物治疗,但如果房颤未先行触发,则无消退;如果房颤过早或心动过速或扑动引发房颤,应尽早消融。所有患者均接受了为期一年的随访,以评估每组窦性心律的维持情况。在12个月的随访检查中,第1组的119名患者(42%)没有AF复发。在第3组的83例患者中,只有27例(33%)没有复发。在84名4名患者中,有67名(80%)没有房颤复发(P <0.0001 vs第三组)。结论:当房室上性心律不齐或过早收缩触发房颤时,第一次房颤消融后复发的患者可能对第二次早期消融有反应。临床试验注册:URL:http://www.clinicaltrials.gov。唯一标识符:NCT01164319。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号